# Synlogic

once a pioneer of "living drug" bacterial therapeutics engineered with gut-restricted kill switches, discontinued its Synpheny-3 Phase 3 trial for phenylketonuria after an internal review suggested it would not meet its primary endpoint;…

Source: https://en.bioecon.ru/companies/synlogic/
Updated: 2026-08-15

- Country: United States
- Ticker: SYBX

## Technologies

- [Intelligent genetic switches (kill switches)](https://en.bioecon.ru/technology/intelligent-genetic-switches-kill-switches/)